Previous 10 | Next 10 |
2023-10-16 08:30:08 ET PCTEL ( NASDAQ: PCTI ) +48% . Essa Pharma ( EPIX ) +32% . Almacenes Exito ( EXTO ) +32% . Ambrx Biopharma ( AMAM ) +32% Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX5...
~ A showcase of PF614 and PF614-MPAR ~ SAN DIEGO, CA / ACCESSWIRE / October 13, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced it has posted to the Compan...
~ Geoff Birkett, CCO of Ensysce, to Chair Meeting, Deliver Opening Remarks and Present a Case Study on Drug Launch Process ~ SAN DIEGO, CA / ACCESSWIRE / October 3, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemi...
~ Study Initiation Brings PF614 One Necessary Step Closer to Phase 3 ~ ~ Trial Results Expected Before Year End 2023 ~ SAN DIEGO, CA / ACCESSWIRE / September 26, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative...
~ Moderated Session to Review Latest Data as Recently Presented ~ SAN DIEGO, CA / ACCESSWIRE / September 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today anno...
~ Positioning Company to Commence Commercialization Strategy ~ SAN DIEGO, CA / ACCESSWIRE / September 14, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announc...
~ Leading Experts Presenting New Clinical Approaches to Treat Severe Pain at PAINWeek Symposium ~ SAN DIEGO, CA / ACCESSWIRE / September 7, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve presc...
SAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that its management has been invited to present at the H.C. Wai...
~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain and Next Generation Solutions ~ SAN DIEGO, CA / ACCESSWIRE / August 14, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety,...
2023-08-11 10:37:56 ET Ensysce Biosciences press release ( NASDAQ: ENSC ): Q2 Non-GAAP EPS of -$0.98. Cash and cash equivalents were $3.8 million as of June 30, 2023, as compared to $1.4 million as of March 31, 2023. For further details see: Ensysce Biosciences N...
News, Short Squeeze, Breakout and More Instantly...
Ensysce Biosciences Inc. Company Name:
ENSC Stock Symbol:
NASDAQ Market:
Ensysce Biosciences Inc. Website:
~ Ready to Commence PF614 Phase 3 Clinical Trial in 2024 ~ ~ Continued Clinical Development of Overdose Protection Breakthrough Therapy ~ ~ Identified Lead Clinical Candidate for Opioid Use Disorder Program ~ SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ensysce Biosciences, Inc....
~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics ~ SAN DIEGO, CA / ACCESSWIRE / July 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative ...
~ Geoff Birkett, Chief Commercial Officer, Provides Insight Following EPHMRA Meeting ~ SAN DIEGO, CA / ACCESSWIRE / June 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain r...